Trial Profile
A Phase I, Multicentre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs AZD 1390 (Primary)
- Indications Brain metastases; Glioblastoma; Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 02 Apr 2024 Planned End Date changed from 28 Feb 2025 to 22 Apr 2026.
- 02 Apr 2024 Planned primary completion date changed from 28 Feb 2025 to 22 Apr 2026.
- 02 Feb 2024 Planned End Date changed from 1 Dec 2026 to 28 Feb 2025.